Page last updated: 2024-08-18

xanthenes and vadimezan

xanthenes has been researched along with vadimezan in 87 studies

Research

Studies (87)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's40 (45.98)18.2507
2000's46 (52.87)29.6817
2010's1 (1.15)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baguley, BC; Thomsen, LL; Wilson, WR1
Baguley, BC; Ching, LM; Joseph, WR2
Baguley, BC; Denny, WA; Kestell, P; McKeage, MJ1
Baguley, BC; Ching, LM; Joseph, WR; Kestell, P; McKeage, MJ; Zwi, LJ1
Atwell, GJ; Baguley, BC; Denny, WA; Li, ZA; Rewcastle, GW1
Baguley, BC; Gavin, JB; Wilson, WR; Zwi, LJ2
Barber, SA; Ching, LM; Perera, PY; Vogel, SN1
Ellis, AG; Kestell, P; Rewcastle, GW; Webster, LK1
Baguley, BC; Ching, LM; Gummer, BH; Joseph, WR; Palmer, BD; Xu, ZF1
Baguley, BC; Ching, LM; Philpott, M2
Bibby, MC; Double, JA; Laws, AL; Matthew, AM1
Baguley, BC; Ching, LM; Joseph, WR; Zhuang, L1
Baguley, BC; Cliffe, S; Hill, RP; Rutland, M; Taylor, ML; Wilson, WR1
Baguley, BC; Cole, G; Li, Z; Thomsen, LL1
Baguley, BC; Ching, LM; Crosier, KE; Joseph, WR1
Baguley, BC; Li, Z; Thomsen, LL; Veszelovszky, E1
Henricson, BE; Li, ZY; Manthey, CL; Perera, PY; Vogel, SN1
Pruijn, FB; Wilson, WR1
Denny, WA; Lee, HH; Li, AE; Patterson, LH; Pullen, SM; Thompson, KM; Wilson, WR1
Arnold, S; Chaplin, DJ; Watts, ME1
Begent, RH; Boden, JA; Boden, R; Boxer, GM; Flynn, AA; Keep, PA; Pedley, RB1
Baguley, BC; Burchell, B; Kestell, P; Lillywhite, KJ; Mackenzie, PI; Miners, JO; Valente, L1
Holford, NH; Pruijn, FB; van Daalen, M; Wilson, WR1
Baguley, BC; Kestell, P; Zhuang, L1
Baguley, BC; Ching, LM; Crosier, KE; Joseph, WR; Philpott, M1
Happerfield, DW; Knowles, RG; Miles, DW; Moilanen, E; Moncada, S; Thomsen, LL1
Baguley, BC; Browne, WL; Ching, LM; Gregory, T; Palmer, BD; Tchernegovski, R1
Baguley, BC; Lash, CJ; Li, AE; Rutland, M; Wilson, WR; Zwi, LJ1
Cowan, DS; Li, AE; Siim, BG; Wilson, WR1
Baguley, BC; Cao, Z; Ching, LM; Joseph, WR; Pang, JH1
Baguley, BC; Cao, Z; Ching, LM; Joseph, WR; Marshall, ES; Mountjoy, KG1
Baguley, BC; Dunlop, I; Kestell, P; Paxton, JW; Rewcastle, GW1
Baguley, BC; Browne, WL; Cao, Z; Ching, LM; Joseph, WR; Mountjoy, KG; Palmer, BD1
Baguley, BC; Ching, LM; Goldsmith, D; Joseph, WR; Körner, H; Sedgwick, JD1
Phillips, RM1
Begent, RH; Boden, R; Boxer, GM; Davies, L; Pedley, RB; Sharma, SK; Springer, CJ; Stribbling, SM1
Ching, LM; Eberly, K; Young, HA; Yu, CR1
Kestell, P; McCall, J; Paxton, JW; Tingle, MD; Zhou, S1
Laux, WT; Palmer, BN; Rutland, MD; Siim, BG; Wilson, WR1
Baguley, BC; Ching, LM; Kestell, P; Muller, G; Palmer, BD; Paxton, JW; Zhao, L1
Kestell, P; Paxton, JW; Tingle, MD; Zhou, S5
Horsman, MR; Murata, R; Overgaard, J1
Baguley, BC; Cao, Z; Ching, LM1
Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Pandey, S1
Ching, LM; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S2
Baguley, BC; Ching, LM; Kestell, P; Philpott, M; Zhao, L; Zhuang, L1
Chin, R; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S1
Baguley, BC; Jameson, MB; Kestell, P; Paxton, JW; Thompson, PI; Tingle, MD; Zhou, SF1
Horsman, MR; Murata, R; Overgaard, J; Siemann, DW1
Baguley, BC; Folkes, LK; Jameson, MB; Kestell, P; Stratford, MR; Zhao, L1
Baguley, BC2
Baguley, BC; Ching, LM; Kestell, P; Zhao, L2
Chiang, D; Chin, R; Kestell, P; Paxton, JW; Zho, S1
Kestell, P; Paxton, JW; Tingle, MD; Zhou, SF1
Beauregard, DA; Brindle, KM; Hill, SA; Pedley, RB1
Bentzen, S; Galbraith, SM; Lodge, MA; Padhani, AR; Rustin, GJ; Stirling, JJ; Taylor, NJ1
Lepler, S; Mercer, E; Rojiani, AM; Siemann, DW1
Baguley, BC; Cao, Z; Ching, LM; Jameson, MB; Kieda, C; Zwain, S1
Kestell, P; Paxton, JW; Zhou, S3
Baguley, BC; Kestell, P; Paxton, JW; Zhou, S3
Galbraith, SM; Gumbrell, L; Hough, D; Jameson, M; Lodge, MA; Padhani, AR; Rustin, GJ; Stirling, JJ; Taylor, NJ; Thompson, P1
Baguley, BC; Wilson, WR1
Baguley, BC; Ching, LM; Fraser, JD; Palmer, BD; Woon, ST1
Atwell, GJ; Denny, WA; Yang, S1
Baguley, BC; Ching, LM1
Horsman, MR; Murata, R1
Horsman, MR; Siemann, DW1
Lee, AE; McKeage, MJ; Pruijn, FB; Shalal-Zwain, S; Siim, BG; Wilson, WR1
Baguley, BC; Ching, LM; Newth, AL; Schooltink, MA; Woon, ST; Zwain, S1
Baguley, BC; Bellenger, K; Evans, BD; Gumbrell, L; Halbert, GW; Harvey, VJ; Jameson, MB; Kestell, P; McCrystal, MR; Porter, DJ; Small, M; Thompson, PI1
Barbera, M; Belluti, F; Bisi, A; Caputo, A; Carrara, M; Gobbi, S; Piazzi, L; Rampa, A; Zampiron, A1
Baguley, BC; Ching, LM; Drummond, CJ; Kieda, C; Reddy, CB; Schooltink, MA; Woon, ST1
Albelda, SM; Ching, LM; Guo, K; Henare, K; Palmer, BD; Tijono, SM; Wang, LC1

Reviews

6 review(s) available for xanthenes and vadimezan

ArticleYear
Small-molecule cytokine inducers causing tumor necrosis.
    Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:7

    Topics: 5-Hydroxytryptophan; Animals; Antineoplastic Agents; Capillary Permeability; Cytokines; Endothelium, Vascular; Flavonoids; Humans; Interferon-alpha; Mice; Microcirculation; Necrosis; Neoplasms; NF-kappa B; Nitric Oxide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

2001
5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Investigational new drugs, 2002, Volume: 20, Issue:3

    Topics: Animals; Antineoplastic Agents; Drug Interactions; Humans; Immunologic Factors; Neoplasms; Xanthenes; Xanthones

2002
Potential of DMXAA combination therapy for solid tumors.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Genetic Therapy; Humans; Neoplasms; Neovascularization, Pathologic; Xanthenes; Xanthones

2002
Enhancement of radiation therapy by vascular targeting agents.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:11

    Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Organophosphorus Compounds; Xanthenes; Xanthones

2002
Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
    Drug metabolism reviews, 2002, Volume: 34, Issue:4

    Topics: Animals; Antineoplastic Agents; Drug Interactions; Forecasting; Humans; Patients; Uridine Diphosphate Glucuronic Acid; Xanthenes; Xanthones

2002
Antivascular therapy of cancer: DMXAA.
    The Lancet. Oncology, 2003, Volume: 4, Issue:3

    Topics: Antineoplastic Agents; Drug Design; Drugs, Investigational; Endothelium, Vascular; Humans; Microcirculation; Neoplasms; NF-kappa B; Xanthenes; Xanthones

2003

Trials

3 trial(s) available for xanthenes and vadimezan

ArticleYear
Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
    British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Breast Neoplasms; Cells, Cultured; Chemokine CXCL10; Chemokines, CXC; Colonic Neoplasms; Endothelium, Vascular; Female; Humans; Interferons; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; RNA, Messenger; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

2002
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Contrast Media; Female; Humans; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Neoplasms; Reproducibility of Results; Xanthenes; Xanthones

2002
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
    British journal of cancer, 2003, Jun-16, Volume: 88, Issue:12

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiovascular System; Female; Humans; Male; Middle Aged; Neoplasms; Nervous System; Treatment Outcome; Xanthenes; Xanthones

2003

Other Studies

78 other study(ies) available for xanthenes and vadimezan

ArticleYear
Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Flavonoids; Mammary Neoplasms, Experimental; Nitric Oxide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xanthenes; Xanthones

1992
Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid.
    Biochemical pharmacology, 1992, Jul-07, Volume: 44, Issue:1

    Topics: Animals; Antineoplastic Agents; BCG Vaccine; Dose-Response Relationship, Drug; Flavonoids; Macrophage Activation; Macrophages; Mice; Mice, Inbred C3H; Thioglycolates; Tumor Cells, Cultured; Xanthenes; Xanthones

1992
Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
    British journal of cancer, 1992, Volume: 66, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Flavonoids; Mice; Mice, Inbred Strains; Mice, Nude; Necrosis; T-Lymphocytes; Thymectomy; Xanthenes; Xanthones

1992
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.
    Cancer chemotherapy and pharmacology, 1991, Volume: 28, Issue:6

    Topics: Animals; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Flavonoids; Male; Mice; Mice, Inbred Strains; Protein Binding; Xanthenes; Xanthones

1991
Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.
    Cancer chemotherapy and pharmacology, 1991, Volume: 28, Issue:6

    Topics: Animals; Antineoplastic Agents; Blood; Blood Cells; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Flavonoids; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Xanthenes; Xanthones

1991
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
    Journal of medicinal chemistry, 1991, Volume: 34, Issue:1

    Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Indicators and Reagents; Mice; Mice, Inbred Strains; Molecular Structure; Structure-Activity Relationship; Xanthenes; Xanthones

1991
Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid.
    British journal of cancer, 1990, Volume: 62, Issue:6

    Topics: Animals; Antineoplastic Agents; Endometrium; Female; Flavonoids; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Necrosis; Thrombosis; Xanthenes; Xanthones

1990
Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation.
    Journal of immunology (Baltimore, Md. : 1950), 1994, Nov-15, Volume: 153, Issue:10

    Topics: Animals; Antineoplastic Agents; Blotting, Northern; Carbohydrate Sequence; Cells, Cultured; Female; Gene Expression Regulation; Genes, Immediate-Early; Immunoblotting; Interferons; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C3H; Molecular Sequence Data; RNA; Signal Transduction; Transcription Factors; Transcriptional Activation; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1994
Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
    Drug metabolism and disposition: the biological fate of chemicals, 1995, Volume: 23, Issue:3

    Topics: Animals; Antineoplastic Agents; Bile; Flavonoids; Glucuronates; Glucuronic Acid; In Vitro Techniques; Liver; Male; Perfusion; Protein Binding; Rats; Rats, Sprague-Dawley; Xanthenes; Xanthones

1995
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
    British journal of cancer, 1995, Volume: 72, Issue:2

    Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Interactions; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Thalidomide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1995
Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:2

    Topics: Aging; Animals; Antineoplastic Agents; Colonic Neoplasms; Crosses, Genetic; Dose-Response Relationship, Drug; Drug Administration Schedule; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1995
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
    British journal of cancer, 1995, Volume: 71, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Colonic Neoplasms; Hemorrhage; Humans; Lung Neoplasms; Mice; Mice, Inbred Strains; Mice, Nude; Necrosis; Species Specificity; Tumor Cells, Cultured; Xanthenes; Xanthones

1995
Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35, Issue:2

    Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Endotoxins; Lipopolysaccharides; Mice; Necrosis; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1994
The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor.
    Pathology, 1994, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Apoptosis; Colonic Neoplasms; Flavonoids; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Microscopy, Electron; Necrosis; Phosphocreatine; Xanthenes; Xanthones

1994
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
    International journal of radiation oncology, biology, physics, 1994, May-15, Volume: 29, Issue:2

    Topics: Aniline Mustard; Animals; Antineoplastic Agents; Drug Synergism; Female; Flavonoids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Regional Blood Flow; Tirapazamine; Triazines; Xanthenes; Xanthones

1994
Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
    Cancer chemotherapy and pharmacology, 1993, Volume: 33, Issue:1

    Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyproheptadine; Flavonoids; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Necrosis; Nitrates; Nitric Oxide; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1993
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
    Cancer research, 1994, Feb-15, Volume: 54, Issue:4

    Topics: Animals; Antineoplastic Agents; Humans; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; RNA, Messenger; Species Specificity; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1994
Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arginine; Canavanine; Colonic Neoplasms; Flavonoids; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Inbred Strains; Necrosis; Nitrates; Nitric Oxide; Nitroarginine; omega-N-Methylarginine; Xanthenes; Xanthones

1993
Dissection of LPS-induced signaling pathways in murine macrophages using LPS analogs, LPS mimetics, and agents unrelated to LPS.
    Progress in clinical and biological research, 1995, Volume: 392

    Topics: Animals; Antibodies, Monoclonal; Gene Expression Regulation; In Vitro Techniques; Lipid A; Lipopolysaccharide Receptors; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C3H; Paclitaxel; Phosphoproteins; Signal Transduction; Xanthenes; Xanthones

1995
Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing.
    Clinical and experimental pharmacology & physiology, 1995, Volume: 22, Issue:11

    Topics: Aniline Mustard; Animals; Antineoplastic Agents; Cell Hypoxia; Mice; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Xanthenes; Xanthones

1995
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
    The British journal of cancer. Supplement, 1996, Volume: 27

    Topics: Acridines; Animals; Anthraquinones; Antineoplastic Agents; Cell Survival; Humans; Intercalating Agents; Mammary Neoplasms, Experimental; Mice; Nitracrine; Oxidation-Reduction; Prodrugs; Xanthenes; Xanthones

1996
Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA.
    The British journal of cancer. Supplement, 1996, Volume: 27

    Topics: Antineoplastic Agents; Blood Coagulation; Capillary Permeability; Cells, Cultured; Endothelium, Vascular; Flavonoids; Humans; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1996
Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.
    Cancer research, 1996, Jul-15, Volume: 56, Issue:14

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality Therapy; Flavonoids; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Radioimmunotherapy; Regional Blood Flow; Serotonin; Tissue Distribution; Transplantation, Heterologous; Xanthenes; Xanthones

1996
Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.
    Cancer research, 1997, Jan-15, Volume: 57, Issue:2

    Topics: Antineoplastic Agents; Glucuronates; Half-Life; Humans; Microsomes, Liver; Xanthenes; Xanthones

1997
Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
    Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:6

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Hypoxia; Drug Synergism; Female; Mammary Neoplasms, Experimental; Melphalan; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Xanthenes; Xanthones

1997
Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
    Oncology research, 1997, Volume: 9, Issue:2

    Topics: Animals; Antineoplastic Agents; Colchicine; Colonic Neoplasms; Dose-Response Relationship, Drug; Flavonoids; Hydroxyindoleacetic Acid; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Serotonin; Time Factors; Vinblastine; Xanthenes; Xanthones

1997
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
    British journal of cancer, 1997, Volume: 76, Issue:12

    Topics: Antineoplastic Agents; Cells, Cultured; Humans; Leukocytes; RNA, Messenger; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1997
Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
    British journal of cancer, 1998, Volume: 77, Issue:3

    Topics: Animals; Antineoplastic Agents; Enzyme Induction; Immunohistochemistry; Mice; Neoplasms, Experimental; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitrites; Ornithine; Xanthenes; Xanthones

1998
Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    British journal of cancer, 1998, Volume: 78, Issue:3

    Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Synergism; Mice; Neoplasm Transplantation; Pentoxifylline; Phthalimides; Thalidomide; Time Factors; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1998
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
    British journal of cancer, 1998, Volume: 78, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Mice; Mice, Inbred C3H; Nitrogen Mustard Compounds; Nitroimidazoles; Prodrugs; Regional Blood Flow; Serotonin; Tirapazamine; Triazines; Xanthenes; Xanthones

1998
Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    International journal of radiation oncology, biology, physics, 1998, Nov-01, Volume: 42, Issue:4

    Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Mice; Mice, Inbred C3H; Neoplasm, Residual; Neoplasms, Experimental; Xanthenes; Xanthones

1998
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:8

    Topics: Animals; Colonic Neoplasms; Cyclosporine; Enzyme-Linked Immunosorbent Assay; Immunosuppressive Agents; Interferon gamma Receptor; Interferon-gamma; Lipopolysaccharides; Mice; Nitric Oxide; Receptors, Interferon; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1998
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Cancer research, 1999, Feb-01, Volume: 59, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Lipopolysaccharides; Liver; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Messenger; Spleen; Stimulation, Chemical; Transplantation, Heterologous; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1999
Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
    Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:4

    Topics: Animals; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Infusions, Intravenous; Injections, Intravenous; Male; Metabolic Clearance Rate; Mice; Protein Binding; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Time Factors; Xanthenes; Xanthones

1999
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    British journal of cancer, 1999, Volume: 80, Issue:5-6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Synergism; Female; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; RNA, Messenger; Spleen; Thalidomide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1999
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
    Cancer research, 1999, Jul-15, Volume: 59, Issue:14

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Hemorrhage; Mice; Mice, Inbred C57BL; Mice, Knockout; Necrosis; Neoplasm Proteins; Neovascularization, Pathologic; RNA, Messenger; RNA, Neoplasm; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

1999
Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
    Biochemical pharmacology, 1999, Jul-15, Volume: 58, Issue:2

    Topics: Antineoplastic Agents; Aziridines; Cell Survival; Cytochrome Reductases; Cytochrome-B(5) Reductase; Enzyme Inhibitors; Flavonoids; Humans; Indolequinones; Indoles; NAD(P)H Dehydrogenase (Quinone); NADPH-Ferrihemoprotein Reductase; Tirapazamine; Triazines; Tumor Cells, Cultured; Vitamin K; Xanthenes; Xanthones

1999
Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Cancer research, 1999, Aug-15, Volume: 59, Issue:16

    Topics: Animals; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; gamma-Glutamyl Hydrolase; Glutamates; Humans; Immunoconjugates; Immunoglobulin Fab Fragments; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Nitrogen Mustard Compounds; Prodrugs; Transplantation, Heterologous; Xanthenes; Xanthones

1999
Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line.
    Biochemical pharmacology, 1999, Oct-01, Volume: 58, Issue:7

    Topics: Animals; Antineoplastic Agents; Cell Line; Cycloheximide; DNA-Binding Proteins; Flavonoids; Interferon-beta; Lipopolysaccharides; Macrophages; Mice; NF-kappa B; Protein Synthesis Inhibitors; STAT1 Transcription Factor; STAT3 Transcription Factor; Trans-Activators; Xanthenes; Xanthones

1999
Determinaton of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection.
    Journal of chromatography. B, Biomedical sciences and applications, 1999, Oct-29, Volume: 734, Issue:1

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Hydroxides; Microsomes, Liver; NADP; Oxidation-Reduction; Phosphoric Acids; Potassium Compounds; Quality Control; Sensitivity and Specificity; Uridine Diphosphate Glucuronic Acid; Xanthenes; Xanthones

1999
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic
    Cancer research, 2000, Aug-15, Volume: 60, Issue:16

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Fibrosarcoma; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Radiopharmaceuticals; Stilbenes; Xanthenes; Xanthones

2000
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Cancer chemotherapy and pharmacology, 2000, Volume: 46, Issue:2

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Bile; Colonic Neoplasms; Female; Half-Life; Mice; Mice, Inbred C57BL; Stereoisomerism; Thalidomide; Time Factors; Tissue Distribution; Xanthenes; Xanthones

2000
Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Drug metabolism and disposition: the biological fate of chemicals, 2000, Volume: 28, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Blotting, Western; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Female; Humans; Hydroxylation; In Vitro Techniques; Isoenzymes; Liver; Male; Methylation; Microsomes, Liver; Middle Aged; Proteins; Subcellular Fractions; Xanthenes; Xanthones

2000
Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
    International journal of radiation biology, 2001, Volume: 77, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood; Digestive System; Dose-Response Relationship, Drug; Female; Kidney; Liver; Lung; Mice; Mice, Inbred C3H; Muscles; Neoplasm Transplantation; Neoplasms; Perfusion; Skin; Spleen; Stilbenes; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Urinary Bladder; Xanthenes; Xanthones

2001
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cancer research, 2001, Feb-15, Volume: 61, Issue:4

    Topics: Animals; Antibodies; Antineoplastic Agents; Chemokine CCL4; Chemokine CXCL10; Chemokines, CXC; Collagen; Colonic Neoplasms; Drug Combinations; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Interferons; Interleukin-12; Laminin; Macrophage Inflammatory Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neovascularization, Physiologic; Proteoglycans; RNA, Messenger; Spleen; Up-Regulation; Xanthenes; Xanthones

2001
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Cancer research, 2001, Mar-01, Volume: 61, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Flavonoids; Gene Dosage; Genetic Therapy; Genetic Vectors; Immunotherapy; Killer Cells, Natural; Lymphocyte Subsets; Lymphoma; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; T-Lymphocytes, Cytotoxic; Thymus Neoplasms; Xanthenes; Xanthones

2001
Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
    The Journal of pharmacy and pharmacology, 2001, Volume: 53, Issue:4

    Topics: Animals; Antineoplastic Agents; Blood Cells; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Humans; Male; Neoplasms; Protein Binding; Rabbits; Rats; Rats, Wistar; Xanthenes; Xanthones

2001
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Diclofenac; Drug Interactions; Female; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Protein Binding; Teratogens; Thalidomide; Xanthenes; Xanthones

2001
Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography.
    Journal of chromatography. B, Biomedical sciences and applications, 2001, Jun-15, Volume: 757, Issue:2

    Topics: Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Reproducibility of Results; Sensitivity and Specificity; Serum Albumin; Xanthenes; Xanthones

2001
Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection.
    Journal of chromatography. B, Biomedical sciences and applications, 2001, Jun-15, Volume: 757, Issue:2

    Topics: Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Ultrafiltration; Xanthenes; Xanthones

2001
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:6

    Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyproheptadine; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Female; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Serotonin Antagonists; Tissue Distribution; Xanthenes; Xanthones

2001
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:6

    Topics: Animals; Antineoplastic Agents; Cyproheptadine; Diclofenac; Drug Interactions; Glucuronides; Hydroxylation; Male; Mice; Microsomes, Liver; Rats; Rats, Wistar; Thalidomide; Xanthenes; Xanthones

2001
Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
    British journal of clinical pharmacology, 2001, Volume: 52, Issue:2

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Interactions; Glucuronides; Humans; In Vitro Techniques; Microsomes, Liver; Models, Biological; Xanthenes; Xanthones

2001
Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
    Xenobiotica; the fate of foreign compounds in biological systems, 2001, Volume: 31, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplastic Agents; Chromatography, High Pressure Liquid; Diazepam; Dose-Response Relationship, Drug; GABA Modulators; Gas Chromatography-Mass Spectrometry; Glucuronidase; Glucuronides; Humans; Hydrogen-Ion Concentration; Hydrolysis; Male; Mice; Mice, Inbred C57BL; Models, Chemical; Phenylbutazone; Protein Binding; Rabbits; Rats; Rats, Wistar; Spectrometry, Mass, Electrospray Ionization; Time Factors; Warfarin; Xanthenes; Xanthones

2001
The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:15

    Topics: Antineoplastic Agents; Cell Culture Techniques; Cytokines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Leukocytes, Mononuclear; Lipopolysaccharide Receptors; Lipopolysaccharides; NF-kappa B; Okadaic Acid; Salicylic Acid; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

2001
Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
    Radiation research, 2001, Volume: 156, Issue:5 Pt 1

    Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Sarcoma, Experimental; Xanthenes; Xanthones

2001
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
    Clinica chimica acta; international journal of clinical chemistry, 2001, Volume: 314, Issue:1-2

    Topics: Angiogenesis Inhibitors; Biomarkers; Calibration; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Electrochemistry; Humans; Hydroxyindoleacetic Acid; Neoplasms; Quality Control; Reference Standards; Regional Blood Flow; Reproducibility of Results; Solutions; Xanthenes; Xanthones

2001
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:1

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Half-Life; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Nitric Oxide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

2002
Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:2

    Topics: Animals; Antineoplastic Agents; Blood Proteins; Female; Humans; Male; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Microsomes, Liver; Protein Binding; Rats; Rats, Inbred WKY; Sex Factors; Xanthenes; Xanthones

2002
High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Feb-05, Volume: 767, Issue:1

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Microsomes, Liver; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Xanthenes; Xanthones

2002
Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
    Xenobiotica; the fate of foreign compounds in biological systems, 2002, Volume: 32, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; In Vitro Techniques; Kidney; Liver; Mice; Microsomes; Microsomes, Liver; Neoplasms; Rabbits; Rats; Species Specificity; Xanthenes; Xanthones

2002
Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
    NMR in biomedicine, 2002, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Mice, SCID; Stilbenes; Transplantation, Heterologous; Xanthenes; Xanthones

2002
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.
    NMR in biomedicine, 2002, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Bibenzyls; Contrast Media; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Muscle, Skeletal; Neoplasms; Reproducibility of Results; Stilbenes; Xanthenes; Xanthones

2002
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
    International journal of cancer, 2002, May-01, Volume: 99, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Necrosis; Neovascularization, Pathologic; Sarcoma, Experimental; Stilbenes; Tumor Cells, Cultured; Xanthenes; Xanthones

2002
Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Sep-05, Volume: 776, Issue:2

    Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Knockout; Microsomes, Liver; Species Specificity; Xanthenes; Xanthones

2002
Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
    The Journal of pharmacy and pharmacology, 2002, Volume: 54, Issue:7

    Topics: Animals; Antineoplastic Agents; Binding Sites; Chromatography, High Pressure Liquid; Kinetics; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Rabbits; Rats; Rats, Wistar; Xanthenes; Xanthones

2002
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
    British journal of cancer, 2002, Aug-12, Volume: 87, Issue:4

    Topics: Animals; Antigens, CD; Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; Mice; Mice, Inbred C57BL; Mice, Knockout; Necrosis; Neoplasm Transplantation; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Serotonin; Time Factors; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

2002
Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
    Oncology research, 2002, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Humans; NF-kappa B; Protein Binding; Tumor Cells, Cultured; Xanthenes; Xanthones

2002
An improved synthesis of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    European journal of medicinal chemistry, 2002, Volume: 37, Issue:10

    Topics: Aniline Compounds; Antineoplastic Agents; Crystallization; Isomerism; Magnetic Resonance Spectroscopy; Nitrates; ortho-Aminobenzoates; Xanthenes; Xanthones

2002
DMXAA: an antivascular agent with multiple host responses.
    International journal of radiation oncology, biology, physics, 2002, Dec-01, Volume: 54, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Hydroxyindoleacetic Acid; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Models, Chemical; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Nitric Oxide; Receptors, Tumor Necrosis Factor; Serotonin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

2002
Combination of vascular targeting agents with thermal or radiation therapy.
    International journal of radiation oncology, biology, physics, 2002, Dec-01, Volume: 54, Issue:5

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Radiation; Flavonoids; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Stilbenes; Temperature; Time Factors; Tumor Cells, Cultured; X-Rays; Xanthenes; Xanthones

2002
Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Biochemical pharmacology, 2003, Jan-01, Volume: 65, Issue:1

    Topics: Animals; Antineoplastic Agents; Enzymes; Humans; Male; Microsomes, Liver; Rats; Rats, Inbred WKY; Xanthenes; Xanthones

2003
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Stilbenes; Time Factors; Xanthenes; Xanthones

2003
NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:8

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; NF-kappa B; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured; Xanthenes; Xanthones

2003
Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Biochemical pharmacology, 2003, Jun-01, Volume: 65, Issue:11

    Topics: Antineoplastic Agents; Binding Sites; Blood Proteins; Cytochrome P-450 Enzyme System; Drugs, Investigational; Humans; Hydrolysis; Metabolic Clearance Rate; Microsomes, Liver; Xanthenes; Xanthones

2003
New derivatives of xanthenone-4-acetic acid: synthesis, pharmacological profile and effect on TNF-alpha and NO production by human immune cells.
    Bioorganic & medicinal chemistry, 2006, Jun-15, Volume: 14, Issue:12

    Topics: Cell Proliferation; Humans; Leukocytes, Mononuclear; Molecular Structure; Nitric Oxide; Stereoisomerism; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones

2006
A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines.
    Oncology research, 2005, Volume: 15, Issue:7-8

    Topics: Animals; Antineoplastic Agents; Biological Assay; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Lymphoma, B-Cell; Mice; Necrosis; NF-kappa B; Structure-Activity Relationship; Xanthenes; Xanthones

2005
Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    British journal of cancer, 2013, Apr-02, Volume: 108, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Collagen; Drug Combinations; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-6; Interleukin-8; Laminin; Leukocytes; Mice; Mice, Nude; Neovascularization, Physiologic; Proteoglycans; Xanthenes; Xanthones

2013